{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:36:23Z","timestamp":1793414183679,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1053\/j.seminhematol.2024.10.008","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T06:42:18Z","timestamp":1729838538000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters"],"prefix":"10.1053","volume":"62","author":[{"given":"Lauren","family":"Merz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Hartley-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Achebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Kanapuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Banjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Quinn","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.008_bib0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0002","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: myeloma, National Cancer Institute, DCCPS, Surveillance Research Program. Accessed August 12, 2024."},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0003","unstructured":"Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2018 [based on November 2020 SEER data submission, posted to the SEER web site, April 2021]. 2021. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2018\/. Accessed May 1, 2024."},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0004","doi-asserted-by":"crossref","unstructured":"Giaquinto AN, Miller KD, Tossas KY, et al. Cancer statistics for African American\/Black People 2022. CA Cancer J Clin. 2022;72(3):202-29. https:\/\/doi.org\/10.3322\/caac.21718. doi: 10.1038\/s41408-023-00961-0.","DOI":"10.3322\/caac.21718"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-023-00961-0","article-title":"Addressing the disparities: the approach to the African American patient with multiple myeloma","volume":"13","author":"Bhutani","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2643-3230.BCD-20-0123","article-title":"Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare","volume":"2","author":"Gormley","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0007","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clml.2023.09.004","article-title":"Creating equitable and inclusive clinical trials for multiple myeloma","volume":"24","author":"Hartley-Brown","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.008_bib0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.10.008_bib0009","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2012-07-443606","article-title":"Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach","volume":"121","author":"Baker","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007087","article-title":"Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases","volume":"13","author":"Manojlovic","year":"2017","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0011","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1038\/bcj.2014.91","article-title":"Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study","volume":"5","author":"Greenberg","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.008_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-019-0177-9","article-title":"Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients","volume":"9","author":"Kazandjian","year":"2019","journal-title":"Blood Cancer J"},{"issue":"7054","key":"10.1053\/j.seminhematol.2024.10.008_bib0013","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/bmj.313.7054.425b","article-title":"Describing race, ethnicity, and culture in medical research. Self defined ethnicity is unhelpful","volume":"313","author":"McAuley","year":"1996","journal-title":"BMJ"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.008_bib0014","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/01.STR.31.5.1013","article-title":"Ethnicity and stroke : beware of the fallacies","volume":"31","author":"Fustinoni","year":"2000","journal-title":"Stroke"},{"issue":"7054","key":"10.1053\/j.seminhematol.2024.10.008_bib0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/bmj.313.7054.425a","article-title":"Describing race, ethnicity, and culture in medical research. \"White\" populations also need to be accurately described","volume":"313","author":"De Bono","year":"1996","journal-title":"BMJ"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.008_bib0016","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-018-0132-1","article-title":"Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry","volume":"8","author":"Baughn","year":"2018","journal-title":"Blood Cancer J"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.10.008_bib0017","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.10.008_bib0018","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.008_bib0019","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.10.008_bib0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/ijc.2910430404","article-title":"A case-control study of multiple myeloma nested in the American Cancer Society prospective study","volume":"43","author":"Boffetta","year":"1989","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.008_bib0021","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/aje\/kwv290","article-title":"Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults","volume":"183","author":"Dankner","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.008_bib0022","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00125-020-05338-7","article-title":"Association between diabetes and haematological malignancies: a population-based study","volume":"64","author":"Gong","year":"2021","journal-title":"Diabetologia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0023","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2021.278772","article-title":"Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls","volume":"107","author":"Shah","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.10.008_bib0024","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1055-9965.EPI-06-0007","article-title":"Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer","volume":"15","author":"Chiu","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/bloodadvances.2023010815","article-title":"Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups","volume":"8","author":"Shah","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.008_bib0026","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3322\/caac.21555","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.10.008_bib0027","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0028","article-title":"Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets","volume":"1","author":"Fiala","year":"2017","journal-title":"JCO Clin Cancer Inform"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.10.008_bib0029","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.008_bib0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.10.008_bib0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-142960","article-title":"Racial differences in multiple myeloma survival and treatment using pooled clinical trial and real-world electronic medical record data","volume":"136","author":"Rusli","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.008_bib0033","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jgo.2020.03.005","article-title":"The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma","volume":"11","author":"Fiala","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.10.008_bib0034","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.22515","article-title":"Racial and ethnic inequities in US oncology clinical trial participation from 2017 to 2022","volume":"6","author":"Pittell","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"32","key":"10.1053\/j.seminhematol.2024.10.008_bib0036","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.22.00504","article-title":"Are pivotal clinical trials for drugs approved for leukemias and multiple myeloma representative of the population at risk?","volume":"40","author":"Casey","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.10.008_bib0037","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0038","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.2020008600","article-title":"When non-Whiteness becomes a condition","volume":"137","author":"Merz","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.10.008_bib0039","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.10.008_bib0040","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/bloodadvances.2024012838","article-title":"Evaluating lab-based eligibility criteria by race\/ethnicity in clinical trials of diffuse large B-cell lymphoma","volume":"8","author":"Khurana","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.10.008_bib0041","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2005-07-3046","article-title":"The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?","volume":"107","author":"Beutler","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0042","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0043","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1172-5-13","article-title":"Alpha-thalassaemia","volume":"5","author":"Harteveld","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.008_bib0045","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3109\/07853890.2015.1091942","article-title":"Increasing prevalence of thalassemia in America: implications for primary care","volume":"47","author":"Sayani","year":"2015","journal-title":"Ann Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.10.008_bib0046","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1542\/peds.2005-0843","article-title":"Changes in the epidemiology of thalassemia in North America: a new minority disease","volume":"116","author":"Vichinsky","year":"2005","journal-title":"Pediatrics"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000360","article-title":"Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene","volume":"5","author":"Reich","year":"2009","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.10.008_bib0048","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.V84.1.44.44","article-title":"Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor","volume":"84","author":"Neote","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0049","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ncomms1265","article-title":"The global distribution of the Duffy blood group","volume":"2","author":"Howes","year":"2011","journal-title":"Nat Commun"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.10.008_bib0050","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.2023.7467","article-title":"Development of duffy null-specific absolute neutrophil count reference ranges","volume":"329","author":"Merz","year":"2023","journal-title":"JAMA"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.10.008_bib0051","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1093\/hmg\/ddaa208","article-title":"The Duffy-null genotype and risk of infection","volume":"29","author":"Legge","year":"2020","journal-title":"Hum Mol Genet"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.10.008_bib0052","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.10.008_bib0053","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"DETERMINATION investigators. Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.10.008_bib0054","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0055","unstructured":"U.S. Food and Drug Administration. Enhancing the diversity of clinical trial populations\u2014 eligibility criteria, enrollment practices, and trial designs guidance for industry. 2020. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial. Accessed August 13, 2024."},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0056","unstructured":"U.S. Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry; availability. 2022. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations. Accessed August 13, 2024."},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0057","unstructured":"U.S. Food and Drug Administration. Collection of race and ethnicity data in clinical trials. 2016. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials. Accessed August 13, 2024."},{"issue":"19","key":"10.1053\/j.seminhematol.2024.10.008_bib0058","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.008_bib0059","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research joint research statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T03:31:26Z","timestamp":1742355086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324001252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0037196324001252"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}